ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1144

Phenotypic Characterization of Childhood Onset Rheumatoid Arthritis

Emily G. Ferrell1, Lori Ponder2, Lauren Minor3, Sheila T. Angeles-Han4, Christine W. Kennedy5, Kelly A. Rouster-Stevens6, Mina Pichavant7, Larry B. Vogler8 and Sampath Prahalad9, 1Emory University School of Medicine, Atlanta, GA, 2Children's Healthcare of Atlanta, Atlanta, GA, 3Department of Pediatrics, Emory University, Atlanta, GA, 4Pediatrics, Emory University, Atlanta, GA, 5Rheumatology Immunology, Emory Children's Center, Atlanta, GA, 6Pediatric Rheumatology, Emory Univ School of Medicine, Atlanta, GA, 7Pediatrics, Emory University School of Medicine, Atlanta, GA, 8Dept of Pediatrics, Emory Univ School of Medicine, Atlanta, GA, 9Pediatrics, Emory Children's Center, Atlanta, GA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Classification criteria and juvenile idiopathic arthritis (JIA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid Factor positive polyarthritis (RF+ poly) is the JIA subtype that resembles adult seropositive RA. However, the ILAR classification criteria for RF+ polyarthritis do not capture all children with childhood onset RA due to specific exclusion criteria: lack of 2 (+) RF tests, <5 active joints in the first 6 months, family history of psoriasis, and (+) HLA-B27 in boys with onset after age 6. The ACR/EULAR criteria used for diagnosing adult RA do not have these exclusions, and they include the highly specific anti-CCP antibodies (ACPA). The current ILAR classification system does not include ACPA. Hence, children who are RF (-) but ACPA (+) may be treated less aggressively and develop complications secondary to undertreated disease. Our objectives are to 1) determine whether RF and/or ACPA (+) children meet ILAR criteria for RF+ poly JIA and 2) assess for significant differences between children who meet RF+ poly criteria and those who are classified as other subtypes.

Methods: Demographic and disease-related data were collected from charts of RF and/or ACPA (+) children. Each child was classified using ILAR criteria, and the ACR/EULAR classification was used to determine whether each child met criteria for adult RA. Children with RF+ poly JIA were compared to those with other subtypes. Nominal variables were compared using Chi square or Fisher’s exact tests, and continuous variables were compared using Student’s T test.

Results: Of 49 children with RF and/or ACPA (+) JIA, 29 (59%) met criteria for RF+ poly JIA (Table 1). Of the 20 who did not, 9 (45%) met criteria for undifferentiated JIA, 6 (30%) for RF- polyarthritis, 3 (15%) for persistent oligoarthritis, and 2 (10%) for extended oligoarthritis. All children with undifferentiated JIA were ACPA (+); 7 had presentations consistent with oligoarthritis, but had 2 positive RF tests; 1 had a father with psoriasis; 1 was an HLA-B27 (+) boy with onset after age 6. Comparison of children who met criteria for RF+ poly JIA to those who did not revealed significant differences in subtype distribution, number meeting ACR/EULAR criteria for RA, and use of steroids. All other features were not significantly different. The ACR/EULAR criteria for RA captured more children with RF and/or ACPA (+) JIA than the ILAR RF+ poly classification (92% vs. 59%).

Conclusion: A significant number of children (41%) with RF and/or ACPA (+) JIA did not meet criteria for RF+ poly JIA, though many of their demographic features and disease measures were similar to children who did. The ACR/EULAR criteria allow a positive RF or ACPA to qualify as positive serology, and these criteria capture more children with RF and/or ACPA (+) JIA. We propose the inclusion of ACPA in future revisions of the JIA classification criteria to improve the specificity of diagnosing childhood onset RA, and we suggest replacing RF+ polyarthritis with RF/ACPA+ JIA.

 

Table 1: Characteristics of ACPA and RF positive children with JIA*

 

RF positive polyarticular JIA

Non-RF positive polyarticular JIA

P value**

Total number

29 (59)

20 (41)

 

Age at symptom onset (mean±SD)

10.3 ± 3.4

9.3 ± 3.9

0.34

Demographic features

     Female gender

     Hispanic ethnicity

     African ancestry

  

22 (76)

7 (14)

9 (18)

  

15 (75)

1 (5)

8 (40)

  

0.95

0.08

0.52

Birth weight (kg; mean±SD)

3.4  ± 0.5

3.3 ± 0.5

0.60

ACPA value (mean±SD)

174.5 ± 100.0

163.2 ± 100.2

0.70

ILAR subtype

     RF + poly

     RF – poly

     Oligo extended

     Oligo persistent

     Undifferentiated

  

29 (100)

0 (0)

0 (0)

0 (0)

0 (0)

  

0 (0)

6 (30)

2 (10)

3 (15)

9 (45)

  

<0.0001

0.002

0.09

0.03

<0.0001

Meets 2010 ACR/EULAR criteria for RA

29 (100)

16 (80)

0.01

Imaging evidence of damage

18 (62)

7 (35)

0.07

Number of affected joints in first 6 months (mean & range)

13 (5-30)

11 (1-48)

0.48

Treatment

     Use of systemic steroids

     Use of DMARD

     Use of biologic

  

20 (69)

28 (97)

19 (66)

  

7 (35)

17 (85)

8 (40)

  

0.02

0.15

0.08

*All values are N(%) of those tested/reporting data for particular variables, except as indicated.  ACPA: anti-citrullinated protein antibody.

**P<0.05 was considered statistically significant

 


Disclosure:

E. G. Ferrell,
None;

L. Ponder,
None;

L. Minor,
None;

S. T. Angeles-Han,
None;

C. W. Kennedy,
None;

K. A. Rouster-Stevens,
None;

M. Pichavant,
None;

L. B. Vogler,
None;

S. Prahalad,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/phenotypic-characterization-of-childhood-onset-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology